Publications
Filters: First Letter Of Last Name is C [Clear All Filters]
Accelerated failure time model for data from outcome-dependent sampling." Lifetime Data Anal 27, no. 1 (2021): 15-37.
"Across-Platform Imputation of DNA Methylation Levels Incorporating Nonlocal Information Using Penalized Functional Regression." Genet Epidemiol 40, no. 4 (2016): 333-40.
"Active Clinical Trials for Personalized Medicine." J Am Stat Assoc 111, no. 514 (2016): 875-887.
"Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51.
" Allele-specific copy-number discovery from whole-genome and whole-exome sequencing." Nucleic Acids Res 43, no. 14 (2015): e90.
"Analysis of multiple survival events in generalized case-cohort designs." Biometrics 74, no. 4 (2018): 1250-1260.
"Analysis of the Proportional Hazards Model with Sparse Longitudinal Covariates." J Am Stat Assoc 110, no. 511 (2015): 1187-1196.
"Analysis of the Proportional Hazards Model with Sparse Longitudinal Covariates." J Am Stat Assoc 110, no. 511 (2015): 1187-1196.
"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J 37, no. 4 (2016): 412-22.
" Assessing Combinability of Phylogenomic Data Using Bayes Factors." Syst Biol 68, no. 5 (2019): 744-754.
"Assessing covariate effects using Jeffreys-type prior in the Cox model in the presence of a monotone partial likelihood." J Stat Theory Pract 12, no. 1 (2018): 23-41.
"Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials." Stat Med 33, no. 27 (2014): 4715-33.
"Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development." Stat Biopharm Res 4, no. 3 (2012): 293-300.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
"The association between copy number aberration, DNA methylation and gene expression in tumor samples." Nucleic Acids Res 46, no. 6 (2018): 3009-3018.
"Asymptotically Normal and Efficient Estimation of Covariate-Adjusted Gaussian Graphical Model." J Am Stat Assoc 111, no. 513 (2016): 394-406.
" Auxiliary marker-assisted classification in the absence of class identifiers." J Am Stat Assoc 108, no. 502 (2013): 553-565.
"Auxiliary variable-enriched biomarker-stratified design." Stat Med 37, no. 30 (2018): 4610-4635.
"Basic concepts and methods for joint models of longitudinal and survival data." J Clin Oncol 28, no. 16 (2010): 2796-801.
"Basic concepts and methods for joint models of longitudinal and survival data." J Clin Oncol 28, no. 16 (2010): 2796-801.
"BayesCTDesign: Two Arm Bayesian Clinical Trial Design with and Without Historical Control Data (R)., 2018.
Bayesian analysis of stochastic volatility-in-mean model with leverage and asymmetrically heavy-tailed error using generalized hyperbolic skew Student's t-distribution." Stat Interface 10 (2017): 529-541.
"Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation." Stat Methods Med Res 24, no. 6 (2015): 836-55.
"Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation." Stat Methods Med Res 24, no. 6 (2015): 836-55.
"Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation." Stat Methods Med Res 24, no. 6 (2015): 836-55.
"Bayesian Case Influence Measures for Statistical Models with Missing Data." J Comput Graph Stat 21, no. 1 (2012): 253-271.
"Bayesian Case-deletion Model Complexity and Information Criterion." Stat Interface 7, no. 4 (2014): 531-542.
"Bayesian clinical trial design using Markov models with applications to autoimmune disease." Contemp Clin Trials 63 (2017): 73-83.
"Bayesian Design of Non-Inferiority Clinical Trials via the Bayes Factor." Stat Biosci 10, no. 2 (2018): 439-459.
"Bayesian design of noninferiority trials for medical devices using historical data." Biometrics 67, no. 3 (2011): 1163-70.
"Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome." Biometrics 70, no. 4 (2014): 1003-13.
"Bayesian estimation of semiparametric nonlinear dynamic factor analysis models using the Dirichlet process prior." Br J Math Stat Psychol 64, no. Pt 1 (2011): 69-106.
"Bayesian frailty models for multi-state survival data." In Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. New York: Springer, 2016.
"Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
"Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Bayesian Inference for Multivariate Meta-regression with a Partially Observed Within-Study Sample Covariance Matrix." J Am Stat Assoc 110, no. 510 (2015): 528-544.
"Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugs." Biostatistics 20, no. 3 (2019): 499-516.
"BAYESIAN INFERENCE OF HIDDEN GAMMA WEAR PROCESS MODEL FOR SURVIVAL DATA WITH TIES." Stat Sin 25, no. 4 (2015): 1613-1635.
"BAYESIAN INFERENCE OF HIDDEN GAMMA WEAR PROCESS MODEL FOR SURVIVAL DATA WITH TIES." Stat Sin 25, no. 4 (2015): 1613-1635.
"Bayesian inference on risk differences: an application to multivariate meta-analysis of adverse events in clinical trials." Stat Biopharm Res 5, no. 2 (2013): 142-155.
"Bayesian inference on risk differences: an application to multivariate meta-analysis of adverse events in clinical trials." Stat Biopharm Res 5, no. 2 (2013): 142-155.
"Bayesian influence measures for joint models for longitudinal and survival data." Biometrics 68, no. 3 (2012): 954-64.
"Bayesian lasso for semiparametric structural equation models." Biometrics 68, no. 2 (2012): 567-77.
" Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian meta-experimental design for evaluating cardiovascular risk." In Quantitative Evaluation if Safety in Drug Development: Design, Analysis and Reporting, 13-38. Boca Raton: Chapman & Hall / CRC Press, 2014.
"Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183.
"Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183.
"Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials." J Comput Graph Stat 26, no. 1 (2017): 121-133.
"Bayesian modeling and inference for clinical trials with partial retrieved data following dropout." Stat Med 32, no. 24 (2013): 4180-95.
"Bayesian modeling and inference for clinical trials with partial retrieved data following dropout." Stat Med 32, no. 24 (2013): 4180-95.
"Bayesian Modeling and Inference for Nonignorably Missing Longitudinal Binary Response Data with Applications to HIV Prevention Trials." Stat Sin 28 (2018): 1929-1963.
"A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309.
"Bayesian multivariate skew meta-regression models for individual patient data." Stat Methods Med Res 28, no. 10-11 (2019): 3415-3436.
"Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"Bayesian Transformation Models for Multivariate Survival Data." Scand Stat Theory Appl 41, no. 1 (2014): 187-199.
"Bayesian Variable Selection for Pareto Regression Models with Latent Multivariate Log Gamma Process with Applications to Earthquake Magnitudes." Geosciences (Basel) 9, no. 4 (2019).
"bcSeq: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens." Bioinformatics 34, no. 20 (2018): 3581-3583.
" Biclustering via sparse clustering." Biometrics 76, no. 1 (2020): 348-358.
"Biclustering with heterogeneous variance." Proc Natl Acad Sci U S A 110, no. 30 (2013): 12253-8.
"Bivariate random effects meta-analysis of diagnostic studies using generalized linear mixed models." Med Decis Making 30, no. 4 (2010): 499-508.
"Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk." Stat Methods Med Res 21, no. 6 (2012): 621-33.
"Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk." Stat Methods Med Res 21, no. 6 (2012): 621-33.
" Case-cohort studies with interval-censored failure time data." Biometrika 104, no. 1 (2017): 17-29.
"CHANGE POINT ANALYSIS OF HISTONE MODIFICATIONS REVEALS EPIGENETIC BLOCKS LINKING TO PHYSICAL DOMAINS." Ann Appl Stat 10, no. 1 (2016): 506-526.
"Checking semiparametric transformation models with censored data." Biostatistics 13, no. 1 (2012): 18-31.
"Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
" Comment." J Am Stat Assoc 111, no. 515 (2016): 942-947.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"A Comparison of Monte Carlo Methods for Computing Marginal Likelihoods of Item Response Theory Models." J Korean Stat Soc 48, no. 4 (2019): 503-512.
"A Comparison of Monte Carlo Methods for Computing Marginal Likelihoods of Item Response Theory Models." J Korean Stat Soc 48, no. 4 (2019): 503-512.
"Composite large margin classifiers with latent subclasses for heterogeneous biomedical data." Stat Anal Data Min 9, no. 2 (2016): 75-88.
"A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews." Stat Methods Med Res 26, no. 2 (2017): 914-930.
"A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews." Stat Methods Med Res 26, no. 2 (2017): 914-930.
"Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
"A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
" Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach." JMIR Hum Factors 6, no. 2 (2019): e12700.
"Data for cancer comparative effectiveness research: past, present, and future potential." Cancer 118, no. 21 (2012): 5186-97.
" Designing penalty functions in high dimensional problems: The role of tuning parameters." Electron J Stat 10, no. 2 (2016): 2312-2328.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Diagnostic Measures for the Cox Regression Model with Missing Covariates." Biometrika 102, no. 4 (2015): 907-923.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Discussion of Laber et al. "Optimal treatment allocations in space and time for on-line control of an emerging infectious disease"." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 779-780.
"Discussion of Laber et al. "Optimal treatment allocations in space and time for on-line control of an emerging infectious disease"." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 779-780.
"